Denis V Sazonov

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

Jun‐ichi Kira, Jin Nakahara, Denis V Sazonov, Takayoshi Kurosawa et autres

BACKGROUND: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. OBJECTIVE: To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia. …

jp, ru, ch, us, de (code pays fourni par la source)

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Amit Bar‐Or, Heinz Wiendl, Xavier Montalbán, Enrique Álvarez et autres

Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved in several countries for relapsing multiple sclerosis (RMS). Objective: To demonstrate the bioequivalence of ofatumumab administered by an autoinjector versus a pre-filled syringe (PFS) and to explore the effect of ofatumumab …

us, de, es, ru, lt, ee, lv, at, cz, ch (code pays fourni par la source)

Sustained Efficacy of Ofatumumab in Relapsing Multiple Sclerosis Patients: Results from Extended Treatment in the Phase 2 APOLITOS Study (2032)

Takahiko Saida, Jin Nakahara, Denis V Sazonov, Takayoshi Kurosawa et autres

To evaluate the efficacy and safety of ofatumumab in Japanese and Russian relapsing MS (RMS) patients.

jp, ru, ch, us (code pays fourni par la source)

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara, Achim Berthele et autres

BACKGROUND: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces …

gb, us, jp, de, es, kr, tr, ru, my, tw (code pays fourni par la source)

SAFETY ASPECTS WITHOUT LOSS OF EFFECTIVENESS IN THE SWITCH OF PATIENTS WITH MULTIPLE SCLEROSIS FROM THE ORIGINAL DRUG GLATIRAMER ACETATE COPAXONE-TEVA ON THE BIOSIMILAR TIMEXON

Taras O. Simaniv, Mariya N. Zakharova, N. Yu. Lashch, Sergey V. Kotov et autres

The article presents the results of safety fi ndings during international multicenter randomized double-blind, active and placebo-controlled, comparative phase 3 trial. 158 patients with relapsing-remitting multiple sclerosis were randomly assigned into 3 groups: Timexon (glatiramer acetate, manufactured by JSC «BIOCAD», Russia), copaxone-Teva …

ru, us (code pays fourni par la source)

Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a

L P Bosenko, V V Vasilovskiy, Larisa I. Volkova, Mariya N. Zakharova et autres

OBJECTIVES: To evaluate efficacy, safety, and tolerability of the treatment with teberif/interferon β-1a, to analyze safety, tolerability and dynamics of key efficacy variables after switching from referent drug rebif to biosimilar teberif in patients with remitting multiple sclerosis (RMS). MATERIAL AND METHODS: …

ru, ua (code pays fourni par la source)

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

E. P. Evdoshenko, N. A. Neofidov, Klara Z. Bakhtiyarova, M.V. Davydovskaya et autres

AIM: To study the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (SPMS) in the Russian population of the EXPAND study. MATERIAL AND METHODS: Ninety-four patients with SPMS from Russia were included in the analysis. Sixty-three patients received …

ru, ch (code pays fourni par la source)

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

E. P. Evdoshenko, N. A. Neofidov, Klara Z. Bakhtiyarova, M.V. Davydovskaya et autres

Evdoshenko EP, Neofidoff NA, Bakhtiiarova KZ, Davydovskaya MV, Kairbekova EI, Kolontareva YuM, Malkova NA, Odinak MM, Popova EV, Sazonov DV, Stoliarov ID, Smagina IV, Fedianin AS, Khabirov FA, Khaĭbullin TI, Khachanova NV, Shchukin IA, Boĭko AN. The efficacy and safety of siponimod …

ru, ch (code pays fourni par la source)

A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Interferon β-1a Formulations for S.C. Administration in Patients with Remitting Multiple Sclerosis: First-Year Results

А. Н. Бойко, L P Bosenko, В В Василовский, Larisa I. Volkova et autres

ru, ua (code pays fourni par la source)

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree, Robert J. Fox et autres

ch, ca, us, gb, de, fr, be, nl (code pays fourni par la source)

A Comparative Placebo-Controlled Clinical Trial of the Efficacy and Safety of Glatiramer Acetate 20 mg in Patients with Remitting Multiple Sclerosis: First-Year Study Results

А. Н. Бойко, N. Yu. Lashch, Svetlana N. Sharanova, Mariya N. Zakharova et autres

ru (code pays fourni par la source)

An impact of glatiramer acetate (timexon) on the signs of neurodegeneration process in the neuronal layer of the retina in patients with relapsing-remitting multiple sclerosis

Denis V Sazonov, Larisa Babenko, Asya Yarmoschuk, E M Didrikh

AIM: To perform a comparative study of the results of optical coherence tomography of the retina in patients with relapsing-remitting multiple sclerosis, treated with glatiramer acetate (timexon). MATERIAL AND METHODS: The study included 19 patients (16 women and 3 men) with relapsing-remitting …

ru, gb (code pays fourni par la source)